IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Fairmount Funds Management LLC

Q3 2024 Holdings

Filed 2024-11-14 | 15 holdings | $1.2B | 13F-HR | View on SEC ↗ · Holdings Table ↗

Sign in to see sub-manager breakdown

IssuerClassCUSIPValue ↓Shares% Portfolio
Axsome Therapeutics Inc(AXSM)COM05464T104$212.1M2,360,07717.2%
Nuvalent Inc(NUVL)COM670703107$172.6M1,687,06414.0%
Apogee Therapeutics Inc(APGE)COM03770N101$120.3M2,048,6479.8%
Spyre Therapeutics Inc(SYRE)COM NEW00773J202$118.2M4,018,1019.6%
Enliven Therapeutics Inc(ELVN)COM29337E102$81.8M3,202,7986.6%
Kiniksa Pharmaceuticals Intl(KNSA)ORD SHS CL AG52694109$80.1M3,204,8416.5%
Oruka Therapeutics Inc(ORKA)COM687604108$78.7M3,211,9226.4%
Viridian Therapeutics Inc(VRDN)COM92790C104$78.4M3,445,8136.4%
Dianthus Therapeutics Inc(DNTH)COM252828108$73.9M2,700,6916.0%
Cogent Biosciences Inc(COGT)COM19240Q201$67.2M6,225,6415.5%
DAY One Biopharmaceuticals Inc(DAWN)COM23954D109$43.2M3,103,4483.5%
Astria Therapeutics Inc(CATBUSD)COM04635X102$39.1M3,554,1293.2%
Bicara Therapeutics Inc(BCAX)COM055477103$32.7M1,284,1692.7%
Zenas Biopharma Inc(ZBIO)COM98937L105$32.0M1,892,8062.6%
Bicycle Therapeutics PLC(BCYC)SPONSORED ADS088786108$2.8M123,5380.2%